[go: up one dir, main page]

MX377781B - Composiciones y metodos para diagnostico y tratamiento del cancer. - Google Patents

Composiciones y metodos para diagnostico y tratamiento del cancer.

Info

Publication number
MX377781B
MX377781B MX2017011794A MX2017011794A MX377781B MX 377781 B MX377781 B MX 377781B MX 2017011794 A MX2017011794 A MX 2017011794A MX 2017011794 A MX2017011794 A MX 2017011794A MX 377781 B MX377781 B MX 377781B
Authority
MX
Mexico
Prior art keywords
diagnosis
treatment
cancer
compositions
methods
Prior art date
Application number
MX2017011794A
Other languages
English (en)
Other versions
MX2017011794A (es
Inventor
Hans- Ulrich Schmoldt
Joycelyn Wüstehube-Lausch
Markus Fiedler
Matin Daneschdar
Ugur Sahin
Original Assignee
Biontech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag filed Critical Biontech Ag
Publication of MX2017011794A publication Critical patent/MX2017011794A/es
Publication of MX377781B publication Critical patent/MX377781B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con el diagnóstico y tratamiento de enfermedades cancerosas, en particular enfermedades cancerosas que expresan Seprase (Fap-alfa; proteína alfa para activación de fibroblastos). Más particularmente, la invención se relaciona con péptidos que se focalizan a Seprase.
MX2017011794A 2015-03-17 2016-03-15 Composiciones y metodos para diagnostico y tratamiento del cancer. MX377781B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/055560 WO2016146174A1 (en) 2015-03-17 2015-03-17 Compositions and methods for diagnosis and treatment of cancer
PCT/EP2016/055601 WO2016146639A1 (en) 2015-03-17 2016-03-15 Compositions and methods for diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
MX2017011794A MX2017011794A (es) 2018-02-19
MX377781B true MX377781B (es) 2025-03-11

Family

ID=52684233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011794A MX377781B (es) 2015-03-17 2016-03-15 Composiciones y metodos para diagnostico y tratamiento del cancer.

Country Status (11)

Country Link
US (1) US10370433B2 (es)
EP (1) EP3271385B1 (es)
JP (1) JP6739132B2 (es)
KR (1) KR102414718B1 (es)
CN (1) CN107531776B (es)
AU (1) AU2016232301B2 (es)
CA (1) CA2979768C (es)
ES (1) ES2747727T3 (es)
HK (1) HK1247931A1 (es)
MX (1) MX377781B (es)
WO (2) WO2016146174A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2972577T3 (es) 2016-12-14 2024-06-13 Purdue Research Foundation Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP)
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
GB201820320D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
EP3993874A4 (en) 2019-07-03 2023-06-28 PeptiDream Inc. Cd38-binding agents and uses thereof
CN118955620A (zh) 2019-07-08 2024-11-15 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
US20220273831A1 (en) * 2019-07-08 2022-09-01 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
CN112409414B (zh) * 2020-12-01 2021-10-26 北京师范大学 锝-99m标记含异腈的FAPI衍生物及制备方法和应用
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CA3206863A1 (en) 2021-01-07 2022-07-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
AU2022397890A1 (en) * 2021-11-29 2024-05-02 Navigo Proteins Gmbh Specific binding molecules for fibroblast activation protein (fap)
WO2024165072A1 (zh) * 2023-02-10 2024-08-15 成都纽瑞特医疗科技股份有限公司 一种多肽化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6084062A (en) * 1996-03-20 2000-07-04 Dyax Corp. Polypeptides that bind to tissue plasminogen activator (tPA)
US6884770B1 (en) * 1998-11-06 2005-04-26 Curis, Inc. Methods and compositions for treating or preventing peripheral neuropathies
US6951839B1 (en) * 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
AU2005287557B2 (en) * 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
FI1996220T4 (fi) * 2006-03-06 2023-11-09 Amunix Pharmaceuticals Inc Strukturoimattomat rekombinanttipolymeerit ja niiden käytöt
MX2010004671A (es) * 2007-12-10 2010-05-27 Hoffmann La Roche Seprasa como marcador para cancer.
CA2844073C (en) * 2010-08-23 2015-10-13 NanoRx, Inc. Policosanol nanoparticles
CN102643847A (zh) * 2011-02-17 2012-08-22 华东理工大学 多基因共表达体系及含二硫键功能性蛋白的生产方法
WO2013170994A1 (de) * 2012-03-27 2013-11-21 Protagen Ag Markersequenzen für rheumatoide arthritis
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide

Also Published As

Publication number Publication date
US10370433B2 (en) 2019-08-06
EP3271385A1 (en) 2018-01-24
EP3271385B1 (en) 2019-07-03
KR20170121215A (ko) 2017-11-01
CN107531776B (zh) 2022-01-25
BR112017018522A2 (pt) 2018-04-17
WO2016146639A1 (en) 2016-09-22
CA2979768C (en) 2022-07-05
NZ734680A (en) 2022-03-25
AU2016232301B2 (en) 2020-12-24
HK1247931A1 (zh) 2018-10-05
JP2018515066A (ja) 2018-06-14
MX2017011794A (es) 2018-02-19
KR102414718B1 (ko) 2022-06-30
ES2747727T3 (es) 2020-03-11
US20180037632A1 (en) 2018-02-08
JP6739132B2 (ja) 2020-08-12
CA2979768A1 (en) 2016-09-22
AU2016232301A1 (en) 2017-09-07
CN107531776A (zh) 2018-01-02
WO2016146174A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12018502429A1 (en) Antibody molecules for cancer treatment
ZA201905488B (en) Tigit- and light-based chimeric proteins
MX2019001920A (es) Arn la terapia contra el cancer.
MX2022001105A (es) Anticuerpos anti tigit.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2015009726A3 (en) Medical uses of cd38 agonists
MX2019010440A (es) Proteinas de union a antigeno anti-tigit y metodos de uso de las mismas.
GEP20217317B (en) Combination therapy for the treatment of cancer
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PH12021551419A1 (en) New conjugated nucleic acid molecules and their uses
WO2012090207A3 (en) Par1 and par2 c-tail peptides and peptide mimetics
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations

Legal Events

Date Code Title Description
FG Grant or registration